PUBLIC COMPANY
save$CRSPCRISPR Therapeutics AG
$CRSP53.55-0.81%Zug, CHupdated 18h ago
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom.
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase1A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
- phase2Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
- phase2A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
- phase1A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- phase2A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
- phase2A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- phase2A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
- —A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
Insider activity
source: SEC Form 4open-market buys + sells
- Mar 23, 26SELLKulkarni Samarth· Chief Executive Officer−$469K↗
- Mar 23, 26SELLPrasad Raju· Chief Financial Officer−$173K↗
- Mar 23, 26SELLKASINGER JAMES R.· General Counsel and Secretary−$149K↗
- Mar 16, 26SELLKulkarni Samarth· Chief Executive Officer−$499K↗
- Mar 16, 26SELLPrasad Raju· Chief Financial Officer−$282K↗
- Mar 16, 26SELLPrasad Raju· Chief Financial Officer−$194K↗
- Mar 16, 26SELLKASINGER JAMES R.· General Counsel and Secretary−$166K↗
- Mar 16, 26SELLPatel Naimish· Chief Medical Officer−$152K↗
- Mar 11, 26SELLKulkarni Samarth· Chief Executive Officer−$517K↗
- Mar 11, 26SELLKASINGER JAMES R.· General Counsel and Secretary−$148K↗
- Feb 19, 26SELLKulkarni Samarth· Chief Executive Officer−$366K↗
- Feb 19, 26SELLKASINGER JAMES R.· General Counsel and Secretary−$111K↗
routine RSU / option mechanics (6)
- Mar 20, 26option exercisePrasad Raju · Chief Financial Officer6,250 sh
- Mar 20, 26grantPrasad Raju · Chief Financial Officer27,500 sh
- Mar 20, 26option exerciseKASINGER JAMES R. · General Counsel and Secretary6,250 sh
- Mar 20, 26grantPrasad Raju · Chief Financial Officer38,499 sh
- Mar 20, 26option exercisePrasad Raju · Chief Financial Officer6,250 sh
- Mar 20, 26grantKASINGER JAMES R. · General Counsel and Secretary25,000 sh
🐶 Hiring Signal
News
- STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATDBiotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry.stat · 18d ago
Data sources
last refreshed just now
Found something off?
comments(0)
5-min edit window · permanent after that